|
業務類別
|
Biotechnology |
|
業務概覽
|
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment. |
| 公司地址
| 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087 |
| 電話號碼
| +1 484 253-1461 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.palvellatx.com |
| 員工數量
| 29 |
| Mr. Matthew E. Korenberg |
Secretary, Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 475.30K |
30/04/2026 |
| Mr. Wesley H. Kaupinen |
Chief Executive Officer, President and Director |
美元 575.00K |
30/04/2026 |
| Ms. Kathleen Goin |
Chief Operating Officer |
美元 481.30K |
30/04/2026 |
| Mr. Jeffrey Martini, PhD |
Chief Scientific Officer |
-- |
30/04/2026 |
| Mr. Ashley Hartmann Kline |
Chief Commercial Officer |
-- |
30/04/2026 |
|
|
| Dr. Elaine J. Heron, M.B.A.,PhD |
Independent Director |
30/04/2026 |
| Mr. Todd C. Davis |
Independent Director |
30/04/2026 |
| Mr. Matthew Pauls, J.D.,M.B.A. |
Independent Director |
30/06/2026 |
| Mr. Christopher Kiritsy |
Independent Director |
30/04/2026 |
| Mr. Wesley H. Kaupinen |
Chief Executive Officer, President and Director |
30/04/2026 |
| Mr. George M. Jenkins |
Chairman of the Board |
30/04/2026 |
| Mr. Tadd S. Wessel |
Independent Director |
30/04/2026 |
| Dr. John Doux, M.D. |
Independent Director |
13/04/2026 |
|
|
|
|
